Healthy Clinical Trial
Official title:
Pain and Placebo - a Study to Examine Relations Between Pain Reporting Accuracy and the Response to Experimental Placebo Model
Good clinical care relies on precise evaluation of patients' conditions. Chronic pain and other neurological and psychiatric diagnoses pose challenges because their assessment depends on subjective patient-reported outcome measures (PROs). The investigators have recently developed the Focused Analgesia Selection Task (FAST), a method that allows assessing pain reporting accuracy. Preliminary results suggest that those who more accurately report their pain show diminished placebo response. The underlying mechanisms for this observation cannot be explained by current theories. Therefore, the investigators have conducted a pilot study to further characterize this relation in healthy population.
Instruments and procedures:
Instruments All stimuli were applied by a contact-heat Thermal Sen-sory Analyzer 2001 system
(Medoc, Ramat-Yishai, Israel) with a 30 x 30mm Peltier surface stimulator, which was attached
by Velcro straps to the volar surface of the forearm of the subjects' hand.
Familiarization session At the beginning of the experimental session, all subjects underwent
short training in order to familiarize them with the device and with the sensations evoked by
the painful stimulation, and to train them to report their perceived pain intensity using the
numerical pain scale. The training included exposure to three short contact-heat stimuli (44,
46.5, and 48°C), each lasting for 7 seconds from the time that the stimulation intensity
reached the destination temperature. The thermode was moved following each stimulus to a
completely distinct, adjacent area of skin. Subjects were asked to report the numerical pain
score (NPS), on a scale ranging from 0, denoting no pain, to 100, denoting the worst pain
imaginable, induced by each stimulus.
Pain reporting accuracy assessment:
The subject's pain reporting accuracy skills was assessed by the FAST, which is based on
recording a subject's pain reports in response to repeated administration of thermal noxious
stimuli of various intensities. During the FAST procedure the thermode was attached to the
ventral surface of the subject's non-dominant arm and the temperature was raised from a
baseline of 32°C, peaked for 3 seconds at 1 of 7 designated temperatures (44°C, 45°C, 46°C,
47°C, 48°C, 49°C, and 50°C), and then decreased down to the baseline. Stimulus rate of rise
and fall was kept constant at 8°C/seconds. Subjects were asked to rate the peak pain
intensity of each stimulus verbally using the NPS. Each temperature was presented 7 times in
a random block-ordered design (49 stimuli in total). Inter-stimulus intervals of 20 seconds
allowed the subject sufficient time to rate the pain they perceived during each stimulus. The
location of the thermode was adjusted every 10 stimuli to minimize sensitization and/or
habituation effects. The duration of the FAST procedure is ~25 minutes.
Placebo assessment:
The placebo effect was assessed using tonic heat delivered at fixed temperature of either 44,
46.5, and 48°C. As was shown by previous studies, these temperatures evokes mild, moderate
and severe pain sensations. During the stimuli, the thermode was attached to the volar
surface of the forearm of the subjects' dominant hand. Baseline temperature was 32.0 °C, with
an increasing temperature rate of 2°C/s and a return-to-baseline temperature rate of 8°C/s.
Pain intensity ratings of heat stimuli were assessed verbally using NPS, at 2, 10 and 20 sec
after the initiation of the stimulus.
Placebo procedure:
Each subject received clinical trial-type instructions before receiving the placebo so that
the condition of the study would be similar to those encountered in typical drug trials.
Subjects consented to participate in a study examining the analgesic effects of a well-known
established pain relief medication. The subjects were told that they were about to receive a
pain relief medication, which is commonly used in clinical practice. Possible adverse effects
of the substance in question were then described, but it was indicated that the investigators
did not typically observe significant adverse effects. Actual pharmacological agents were not
administered.
Study design:
All experiments were conducted in the same setting, by the same investigator. The experiment
was performed in a quiet room with an ambient temperature of 23°C. After the familiarization
stage, the experiment begun with delivery of the FAST. After a 10 min break, subjects
received the three tonic heat stimuli, each lasting 20 sec long, in a pseudo-random order
with 60 sec break between each stimulus. Thereafter each subject was given a placebo pill. In
order to evaluate placebo effect, the tonic heat stimuli were administered 20 minutes after
placebo intake maintaining the same stimuli order.
The net placebo effect (Δ) was calculated as the difference between the mean NPS of the mild,
moderate, and severe pain stimuli administrated before the placebo (Pre-placebo) minus the
same after placebo (Post-placebo). The placebo effect in percent was calculated as the ratio
of Post-placebo to Pre-placebo double 100. Positive values indicate efficient placebo effect.
The total duration of the experimental session was approximately 1 hours and 30 minutes.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |